COVID-19 y diabetes mellitus: una relación bidireccional
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
El coronavirus 2 del síndrome respiratorio agudo grave (SARS-CoV-2) es el agente causal de la enfermedad por coronavirus 2019 (COVID-19). La diabetes es una de las comorbilidades más frecuentes en personas con COVID-19, con una prevalencia que varía según los estudios entre el 7 y el 30%. Los diabéticos infectados con SARS-CoV-2 tienen una tasa más alta de admisión hospitalaria, neumonía severa y mayor mortalidad en comparación con sujetos no diabéticos. La hiperglucemia crónica puede comprometer la inmunidad innata y la inmunidad humoral. Además, la diabetes se asocia con un estado inflamatorio crónico de bajo grado que favorece el desarrollo de una respuesta inflamatoria exagerada y, por tanto, la aparición del síndrome de distrés respiratorio agudo. Evidencia reciente ha demostrado que el SARS-CoV-2 también es capaz de producir un daño directo al páncreas, que podría empeorar la hiperglucemia e incluso inducir la aparición de diabetes en sujetos previamente no diabéticos. Las estrategias terapéuticas deben dirigirse a facilitar el acceso de los pacientes al sistema sanitario. El control de la glucemia y de las comorbilidades debe ser individualizado a fin de reducir la incidencia de complicaciones y disminuir la carga en los sistemas de salud. En este artículo revisaremos los mecanismos fisiopatológicos que explican la relación bidireccional entre COVID-19 y diabetes mellitus, su implicación en el pronóstico y el manejo de la hiperglucemia en este grupo de pacientes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
COVID-19 and Italy: what next?
Remuzzi, A., & Remuzzi, G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30627-9 · Cited by 3,119
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Diabetes is a risk factor for the progression and prognosis of COVID‐19
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3319 · Cited by 1,404
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
New-onset diabetes in Covid-19
Rubino, F., Amiel, S. A., Zimmet, P., Alberti, G., Bornstein, S., Eckel, R. H., Mingrone, G., Boehm, B., Cooper, M. E., Chai, Z., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2018688 · Cited by 801
Middle East Respiratory Syndrome
Arabi, Y. M., Balkhy, H. H., Hayden, F. G., Bouchama, A., Luke, T., Baillie, J. K., Al-Omari, A., Hajeer, A. H., Senga, M., Denison, M. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsr1408795 · Cited by 518
Research works printed but not linked: 20
- Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med., 382, 1708, 10.1056/NEJMoa2002032 · DOI · Paper page
- De Almeida-Pititto, 2020, Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis, Diabetol Metab Syndr., 12, 75, 10.1186/s13098-020-00586-4 · DOI · Paper page
- Totura, 2015, Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection, mBio., 6, e00638-15, 10.1128/mBio.00638-15 · DOI · Paper page
- Iacobellis, 2020, COVID-19 and diabetes: Can DPP4 inhibition play a role?, Diabetes Res Clin Pract., 162, 108125, 10.1016/j.diabres.2020.108125 · DOI · Paper page
- Lima, 2010, Sistema renina angiotensina y riesgo cardiometabólico, Rev Venez Endocrinol Metab., 8, 3
- Gheblawi, 2020, Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th Anniversary of the Discovery of ACE2, Circ Res., 126, 1456, 10.1161/CIRCRESAHA.120.317015 · DOI · Paper page
- South, 2020, COVID-19, ACE2, and the cardiovascular consequences, Am J Physiol Heart Circ Physiol., 318, H1084, 10.1152/ajpheart.00217.2020 · DOI · Paper page
- Jaeckel, 2002, Viruses and diabetes, Ann N Y Acad Sci., 958, 7, 10.1111/j.1749-6632.2002.tb02943.x · DOI
- Liu, 2020, ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection, Clin Gastroenterol Hepatol., 18, 2128, 10.1016/j.cgh.2020.04.040 · DOI · Paper page
- Zhu, 2020, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, Cell Metab., 31, 1068, 10.1016/j.cmet.2020.04.021 · DOI · Paper page
- Sharma, 2020, Metformin in COVID-19; a possible role beyond diabetes, Diabetes Res Clin Pract., 164, 108183, 10.1016/j.diabres.2020.108183 · DOI · Paper page
- Pal, 2020, Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?, Diabetes Res Clin Pract., 163, 108146, 10.1016/j.diabres.2020.108146 · DOI
- Iacobellis, 2020, COVID-19 and diabetes: Can DPP4 inhibition play a role?, Diabetes Res Clin Pract., 162, 108125, 10.1016/j.diabres.2020.108125 · DOI · Paper page
- Carboni, 2020, Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?, Med Hypotheses., 140, 109776, 10.1016/j.mehy.2020.109776 · DOI
- Bellido, 2020, Consecuencias de la COVID-19 sobre las personas con diabetes, Endocrinol Diabetes Nutr., 67, 355, 10.1016/j.endinu.2020.04.001 · DOI
- Pérez, 2020, Insulin therapy in hospitalized patients, Am J Ther., 27, e71, 10.1097/MJT.0000000000001078 · DOI · Paper page
- Bornstein, 2020, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol., 8, 546, 10.1016/S2213-8587(20)30152-2 · DOI · Paper page
- Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in Covid-19, N Engl J Med., 382, e102
- Riddle, 2020, COVID-19 in people with diabetes: Urgently needed lessons from early reports, Diabetes Care., 43, 1378, 10.2337/dci20-0024 · DOI
- Vivas, 2020, Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del grupo de trabajo de trombosis cardiovascular de la Sociedad Española de Cardiología, Rev Esp Cardiol., 73, 749, 10.1016/j.recesp.2020.04.006 · DOI
Cited by
Spampinato, M., Carota, G., Sferrazzo, G., Fuochi, V., Distefano, A., Ronsisvalle, S., Sipala, F., Giuffrida, R., Furneri, P. M., Di Rosa, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122845 · Cited by 16
“The agent responsible for COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which promotes lung distress syn rome due to a serious chronic inflammatory pattern [13].”
BackgroundInfluential
Metadata
- Authors
- Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W., & Contreras, M.
- Venue
- Clínica e Investigación en Arteriosclerosis
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 33
- Issue
- 3
- Pages
- 151-157
- ISSN
- 0214-9168 (ISSN-L)
- OpenAlex
- W3087544127
- Cited by
- 172
- References
- 11
- FWCI
- 3.41
- Type
- journal article
- Language
- es
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 y diabetes mellitus: una relación bidireccional. https://app.cochat.ai/papers/10.1016/j.arteri.2020.10.001
- The paper
- Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W., & Contreras, M. (2021). COVID-19 y diabetes mellitus: una relación bidireccional. Clínica e Investigación en Arteriosclerosis. https://doi.org/10.1016/j.arteri.2020.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.